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Background: Because breast cancer is a major public health issue, it is particularly important to measure the quality
of the care provided to patients. Survival rates are affected by the timeliness of care, and waiting times constitute
key quality criteria. The aim of this study was to develop and validate a set of quality indicators (QIs) relative to the
timeliness and organisation of care in new patients with infiltrating, non-inflammatory and metastasis-free breast
cancer undergoing surgery. The ultimate aim was to use these QIs to compare hospitals.
Methods: The method of QI construction and testing was developed by COMPAQ-HPST. We first derived a set of 8
QIs from consensus guidelines with the aid of experts and professional associations and then tested their
metrological properties in a panel of 60 volunteer hospitals. We assessed feasibility using a grid exploring 5
dimensions, discriminatory power using the Gini coefficient as a measure of dispersion, and inter-observer reliability
using the Kappa coefficient.
Results: Overall, 3728 records were included in the analyses. All 8 QIs showed acceptable feasibility (but one QI was
subject to misinterpretation), fairly strong agreement between observers (Kappa = 0.66), and wide variations in
implementation among hospitals (Gini coefficient< 0.45 except for QI 6 (patient information)). They are thus
suitable for use to compare hospitals and measure quality improvement.
Conclusions: Of the 8 QIs, 3 are ready for nationwide implementation (time to surgery, time to postoperative
multidisciplinary team meeting (MDTM), conformity of MDTM). Four are suitable for use only in hospitals offering
surgery with on-site postoperative treatment (waiting time to first appointment after surgery, patient information,
time to first postoperative treatment, and traceability of information relating to prognosis). Currently, in the French
healthcare system, a patient receives cancer care from different institutions whose databases cannot as yet be easily
merged. Nationwide implementation of QIs covering the entire care pathway will thus be a challenge.
Keywords: Breast cancer, Quality indicators, Quality of health care, Timeliness of care* Correspondence: gerard.nitenberg@igr.fr
1INSERM-COMPAQ-HPST project, Institut de Cancérologie Gustave Roussy,
114 rue Edouard Vaillant, Villejuif 94805, FRANCE
Full list of author information is available at the end of the article
© 2012 Ferrua et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Ferrua et al. BMC Health Services Research 2012, 12:167 Page 2 of 9
http://www.biomedcentral.com/1472-6963/12/167Background
Breast cancer is a major public health issue. It has the
highest incidence amongst cancers in women (52,000
new cases in 2010) and is the first cause of death in
women aged 35–65 years in France (11,300 deaths in
2008) [1]. However, measuring quality of care delivered
to breast cancer patients is a challenging issue. In 2004,
the United States Federal Agency for Healthcare Re-
search and Quality (AHRQ) highlighted the paucity and
need to develop validated quality measures to assess the
quality of breast cancer care [2]. This need for “reliable,
validated quality measures [. . .] to afford accountability,
improvement, and research” was reiterated many times
in the USA and in Europe.
Since then, European guidelines for quality assurance,
produced under the auspices of the European Commis-
sion, have listed 39 performance indicators for screening
and diagnosis [3]. A 2010 position paper from the Euro-
pean Society of breast cancer specialists (EUSOMA) has
proposed 17 main quality indicators (QIs) covering
diagnosis, staging, surgery and loco-regional treatment,
systemic treatment, counselling, follow-up and rehabili-
tation [4]. In France, the development of QIs in breast
cancer care was flagged as a high priority in 2007. The
treatment plan for each cancer patient has now to be
discussed in a multidisciplinary team meeting (MDTM)
held according to the rules laid down by the French
National Cancer Institute (Institut National du Cancer -
INCa) and the French National Authority for Health
(Haute Autorité de Santé - HAS) [5,6].
Many of the QIs developed in the wake of the 2004
AHRQ report have been quality of life and patient satis-
faction indicators [2]. However, more recently, in view of
the importance given to waiting times by patients and
many health care organisations, emphasis has also been
placed on QIs measuring the timeliness of care [7-11].
The EUSOMA position paper proposes time to obtain
mammography results, time between mammography
results and the first consultation or between the core bi-
opsy and surgical excision [4]. The second French na-
tional Cancer Plan (2009–2013) has urged that more is
learnt about waiting times in order to reduce inequalities
in access to care that may arise from undue delay [12].
Deviations from guidelines on timeliness can adversely
affect 5-year survival rates [13-15], and patients who re-
ceive their test results promptly are less prone to anxiety
[16-19].
To respond to this enquiry from the French health au-
thorities, there is a need for simple, validated QIs that
can be used to measure and compare quality of care in
hospitals in order to identify room for improvement.
Key methodological concerns, on which depends QI val-
idity, are standardisation of data collection, reducing the
workload of collection, and monitoring of QI inter-hospital variability. Only validated QIs can be implemen-
ted nationally or internationally, for instance in quality
improvement programmes or paying for quality
schemes, or used for public reporting.
The objective of this study was to establish the validity,
for comparing hospitals, of a simple set of 8 easy-to-use
QIs that assess the timeliness of key steps in the care of
patients with infiltrating, non-inflammatory and
metastasis-free breast cancer undergoing surgery.
Methods
Setting
The task of developing QIs for breast cancer manage-
ment was delegated by the French authorities to the re-
search project COMPAQH (COordination for Measuring
Performance and Assuring Quality in Hospitals). COM-
PAQH’s remit is to develop QIs for monitoring quality
in French hospitals and to design ranking methods and
pay-for-quality programmes [20]. The project is run by
INSERM (French National Institute for Health and
Medical Research) and is sponsored by the French
Ministry of Health and HAS which, together in 2003,
listed 9 priority areas in need of quality improvement:
pain management, practice guidelines, human resources
management, iatrogenic events, nutritional disorders, ac-
cess to care, taking account of patients’ views, coordin-
ation of care, and continuity of care. Quality of breast
cancer care comes under the topic “practice guidelines”
[21,22].
QI development in breast cancer care began in 2007
as a partnership between COMPAQH, the French Na-
tional Federation of Cancer Centres (FNLCC), HAS,
INCa, the Société Française de sénologie et de pathologie
mammaire (SFSPM) and the Collège National des Gyné-
cologues et Obstétriciens français (CNGOF). Attention
was focussed on “new patients with infiltrating, non-
inflammatory and metastasis-free breast cancer undergo-
ing surgery within the institution” as this was the main
concern of experts in the field and of consulting physi-
cians. “New patients” were women with unilateral breast
cancer who had never undergone treatment for breast
disease, and who had not yet been seen in consultation
or been admitted to the hospital for breast disease. We
chose “infiltrating, non-inflammatory breast cancer” as
this is the most common type of breast cancer (about
75 % of all cases) and constitutes a homogeneous popu-
lation. Surgery is the primary treatment for most
patients with metastasis-free T0 to T2 tumours.
QI selection
COMPAQ-HPST has a unique methodology for devel-
oping QIs [20,23,24] (Figure 1). The QIs for this study
were designed with the help of experts in the field of
breast cancer, submitted to SFSPM and CNGOF for their
Figure 1 Steps in the development of QIs for breast cancer care by COMPAQ-HPST.
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consulting physicians in breast cancer. A list of criteria and
items was drawn up for each QI. It was based on French
practice guidelines for breast cancer management, legal
regulations, and consensus-based guidance [21,22,25]. Fac-
tors influencing choice of criteria were: high level of evi-
dence (level 1 whenever possible); discriminatory power (in
view of variations observed in practice); practices in areas
that were not subject to rapid change and where consider-
able improvement could be expected; applicability to all
the hospitals in our sample; a precise working definition of
the criterion that could be shared by all; and easy, standar-
dised data collection. The number of criteria was restricted
to 8 in order to lighten the burden of the participating hos-
pitals. These QIs covered the care process as best possible.QI development and testing
Two tests were performed, first a preliminary test of QI
feasibility in a small number of hospitals, then a larger
scale test to measure QI performance.
For the preliminary test, performed in 2008, we asked
23 hospitals performing breast cancer surgery (including
20 comprehensive cancer centres) whether they would
be willing to test the 8 QIs using their data for 2006.
They assessed QI feasibility using a validated grid of 12
items exploring 5 dimensions (QI acceptability by staff,
their understanding of the QI, their availability to re-
spond in the allotted time, the ability of the hospital and
the IT system to collect and handle the necessary data,
and the workload) [26]. At the end of the test, we also
assessed QI relevance as given by inter-hospital variabil-
ity and deviation from expected performance.For the second test (July–October 2009), we approached,
via French hospital federations, all 633 hospitals perform-
ing breast cancer surgery in France (351 public, 231 private
not-for-profit, and 51 private profit-making organisations).
We assessed inter-hospital variability, internal validity
(i.e. whether the QI really measured what it was intended
to measure both from qualitative and quantitative points of
view), and inter-observer reproducibility. Assessment was
double-blind on 20 medical records from each of 14 hospi-
tals. None of the QIs required adjustment.
Data collection
For each test in each hospital, 80 patient records were
analysed manually. This number was a compromise be-
tween acceptable workload and statistical validity [27,28].
The records were selected randomly from the PMSI data-
base (Programme de médicalisation des systèmes d’infor-
mation) which reports diagnosis-related group (DRG)
statistics in a public hospital setting. The selected DRG
code was breast cancer surgery. Apart from the 80
records for analysis, 20 additional records were also
selected in the event of exclusions. Each hospital received
an explanatory guide on the 8 QIs and a grid with




For any given QI, at least 30 completed grids were
required per hospital to support the assumption of a
Gaussian distribution and to compute confidence inter-
vals. This meant that, for any given QI, only those hospi-
tals with at least 30 medical records for this QI were
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hospital variability was given by QI score variance and
the Gini coefficient which measures score dispersion.
Variability (i.e. discriminatory power) is high if the Gini
coefficient is under 0.2 and low if it is above 0.5 [29]. In-
ternal validity was given by the overall concordance rate
and inter-observer reproducibility by the Kappa coeffi-
cient [30,31]. We used SAS version 8.1 software (SAS
Institute Inc, Cary, NC).Results
Choice of QIs and feasibility test results
The working group established a list of 8 QIs: waiting
time to first appointment with surgeon, time to surgery,
time to postoperative MDTM, waiting time to appoint-
ment after surgery, time to first postoperative treatment,
patient information, traceability of information relating
to prognosis, and conformity of postoperative MTDM
(Table 1).
All the 23 hospitals (3 public, 20 cancer centres) taking
part in the feasibility test completed and returned the
grids. They randomly selected 2044 medical records: in-
clusion criteria were not met in 274 records, so 1770
(72 %) were included in our analysis. All QIs, except QITable 1 Tested QIs
QI 1 Waiting time to first appointment with surgeon:
Median time to obtain first appointment
with surgeon [1]
QI 2 Time to surgery: Proportion of patients undergoing
surgery within 21 days of the first appointment
with surgeon [1]
QI 3 Time to postoperative MDTM: Proportion of patients
whose records were discussed in a MDTM held within
14 days of surgery [1]
QI 4 Waiting time to appointment after surgery:
Proportion of patients given appointment relative to MDTM
proposals within 14 days of MDTM [1]
QI 5 Time to first postoperative treatment: Proportion of patients
whose first postoperative treatment was initiated within 30 days
of urgery in the event of chemotherapy and within 56 days in
the event of radiotherapy [9]
QI 6 Patient information: Proportion of patients receiving full
information before surgery as detailed in article 40 of the
French national Cancer Plan [15]
QI 7 Traceability of information relating to prognosis:
Proportion of patients whose medical records provide
all the diagnostic and prognostic informationa
needed to initiate treatment [9,10,12]
QI 8 Conformity of postoperative MDTM: Proportion of
patients for whom the postoperative MDTM was held
according to the rules laid down in the French Health Ministry
circular [1,13,16,23]
a Family history of cancer, age, tumour size, histological type, age, surgical
margins, number of analysed and invaded lymph nodes, histological grading,
steroid hormone status and measurement, immunohistochemical expression
of cERBb2 (HER2).1 (time to first appointment with surgeon), showed fair
feasibility and high inter-hospital variability.
QI 1 presented ambiguities with regard to wording.
Hospitals understood “time to first appointment” (QI 1)
differently. Some hospitals thought that it was the date
the patient’s medical record had been created, some that
it was the date when the patient had called the hospital
for an appointment, and some that it was the date on
the GP’s letter requesting an appointment for the pa-
tient. Because of this ambiguity, QI 1 was reserved for
the hospital’s information and was excluded from the
hospital comparisons below.
QI performance and inter-hospital comparisons
Of the 633 hospitals performing breast cancer surgery,
70 accepted to participate in the testing of QI perform-
ance. Of the 70 participating hospitals, 60 completed
and returned the grids (28 public, 10 private, and 22
not-for-profit privately owned organisations which
included 20 cancer centres) (Figure 2). The reasons for
the 10 drop-outs are given in the footnote to the flow-
chart in Figure 2. The 60 hospitals randomly selected
5215 medical records but we retained only those
(n = 5043) that came from the 54 hospitals that had at
least 30 records for at least one QI. From 6 to 21 hospi-
tals, depending upon the QI, did not reach the required
threshold of at least 30 medical records in order to be
included in hospital comparisons.
The 54 hospitals were situated in different regions of
France and differed in their status (public/private) and
number of beds. All except one met the threshold vol-
ume of activity (> 30 breast cancer surgeries/year) that
is required by French health authorities. The breakdown
according to annual volume of activity was as follows:
28–80 operations (n = 6 hospitals), 122–197 (n = 11),
205–377 (n = 13), 476–945 (n = 18), 1036–1873 (n = 6).
We analysed 3624/5043 records (72 %) from the 54
hospitals. The main reasons for exclusions are given in
the footnote to Figure 2. The incidence of missing data
was by decreasing rank order: 40.6 % (1471/2153) for
date of adjuvant therapy, 26.5 % (960/2664) for date of
the postoperative appointment, 11.1 % (402/3222) for
date of the postoperative MDTM, 8.8 % (319/3305) for
the first appointment with the surgeon, and 0.4 % (9/
3615) for the date of surgery.
QI 2 (“time to surgery”) was subject to misinterpret-
ation: it was not clear whether it referred to (i) the ap-
pointment when the decision to perform surgery was
taken or (ii) the appointment when the surgeon diag-
nosed suspected cancer and ordered tests before decid-
ing to operate. Q2 was used, without modification, in
the hospital comparisons.
Table 2 gives for each QI the number of hospitals
included in hospital comparisons, the mean score (i.e.
Figure 2 Flow-chart of hospital and medical record numbers. * Reasons for drop-outs: heavy workload (n = 5), unavailable data (n = 3), no
response (n = 2). ** Reasons for exclusions: non-infiltrating or non-inflammatory breast cancer (mainly carcinoma in situ) (n = 414, 28 %), prior
treatment for breast cancer (n = 597, 40 %), neo-adjuvant chemotherapy (n = 310, 21 %), bilateral breast cancer (n = 125, 8 %), and unavailable
records (n = 41, 3 %). *** NA: not included in analysis as wording ambiguous according to results of feasibility test.
Ferrua et al. BMC Health Services Research 2012, 12:167 Page 5 of 9
http://www.biomedcentral.com/1472-6963/12/167mean percentage of patients with medical records that
met the criteria outlined in Table 1) with ranges and
standard deviations, and the Gini coefficient which mea-
sures dispersion. Scores varied widely, revealing substan-
tial room for improvement in hospitals for all QIs, in
particular QI 6 (patient information) and QI 8 (conform-
ity of postoperative MTDM), which had the lowest mean
scores. The Gini coefficient was <0.3 for all QIs (except
QI 6 and QI 8) indicating that the power of the QIs to
discriminate among hospitals was high (Figure 3). In the
internal validity test, the overall discordance rate (lack of
reproducibility) was 6.7 % (2.5–13.6). The Kappa coeffi-
cient score of 0.66 was indicative of fairly strong inter-





QI 1 Not applicable
QI 2 49 58.2 (17.4–90.9)
QI 3 47 60.4 (1.4–98.7)
QI 4 39 84.5 (26.5–100)
QI 5 39 47.5 (11.2–91.5)
QI 6 54 12.8 (0–100)
QI 7 54 70.3 (4–98.7)
QI 8 54 46 (0–100)
a Mean percentage of patients with medical records that met the criteria outlined i
performance for each QI.Discussion
Having defined quality as compliance with the care
process, as this has been shown to be associated with pa-
tient outcomes, we developed 7 process QIs relating to
the timeliness and organisation of breast cancer care. All 7
QIs were robust as indicated by their metrological proper-
ties and feasibility. In addition, all 7 highlighted consider-
able inter-hospital variability, thus revealing that there is
substantial room for improvement in the quality of care.
Three of the 7 QIs are ready for nationwide implemen-
tation, namely, QI 2 (time to surgery), QI 3 (time to post-
operative MDTM), and QI 8 (conformity of postoperative
MDTM). Although some hospitals misunderstood the











n Table 1. There was significant divergence (<0.001) from expected
Figure 3 Comparison among hospitals using QI 3. (Proportion of patients undergoing postoperative MDTM 14 days after surgery). The result
for each hospital (anonymous on the ordinate) is given by a horizontal line that represents confidence intervals (CI) (90 % CI - blue; 99 % CI -
black). The vertical line gives the overall mean score for all hospitals and is used for benchmarking.
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however, since been clarified with a view to nationwide
implementation of this QI. QI 2 now refers unambigu-
ously to the date of the appointment when the decision to
perform surgery is taken and not to the date of the ap-
pointment when the surgeon diagnoses suspected cancer
and orders tests before deciding to operate.
The four other validated QIs (QI 6 – patient informa-
tion, QI 4 – waiting time to first appointment after sur-
gery, QI 5 – time to first postoperative treatment, and
QI 7 – traceability of information relating to prognosis)
are applicable only to hospitals that can offer both sur-
gery and postoperative radio- or chemotherapy. Com-
paring all hospitals is rather hazardous as data for these
QIs was often missing (11 %–40 % missing data). QI 6
had a very low mean conformity score (12.8 %) because
of poor traceability of the information given to patients.
An 8th QI we developed (QI 1 – waiting time to first
appointment with the surgeon) proved to be too am-
biguous to be used for comparisons among hospitals.
The external validity of our results may be considered
satisfactory because (i) our patient sample was fairlyrepresentative as the 70 volunteer hospitals were a good
reflection of available facilities for breast cancer care in
France, (ii) it was homogeneous as we focussed on a
subset of breast cancer patients, (iii) the number of
audited and analysed medical records was large, (iv)
results were insensitive to the reactive effects of testing
and reactive settings because of the retrospective nature
of the audit.
Our results reflect real-life conditions, i.e. the tech-
nical and organisational constraints observed when
implementing QIs in hospitals. We anticipated the pro-
blems, taking into account the absence of validated qual-
ity measures of breast cancer care, leading to define
quality as compliance with the process of care that has
been shown to correlate with patient outcome. A sys-
tematic review, published in 2006, underlined the pau-
city of validated indicators of quality measures in breast
cancer care and the need to develop “reliable, validated
quality measures [. . .] to afford accountability, improve-
ment, and research” [32]. Several health care facilities
have emphasized the importance of measuring timeliness
of care from screening to pathology results, allowing to
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patient centred care) when patients were asked which
aspects of care they would improve if they could, aspects
relating to waiting times were most frequently mentioned
[7]. So we decided to concentrate on timely access as a
good representative of “quality care”.
Although we tried to forestall many of the problems
that might arise when designing our QIs, we neverthe-
less had to contend with several hurdles.
The first hurdle was absence of all the required in-
formation in the French PMSI database which was
used to randomly select the 80 medical records. We
used restrictive inclusion criteria (“infiltrating, non-
inflammatory breast cancer”) to obtain a homogeneous
population. We excluded patients with carcinoma in situ
and patients with prior breast cancer treatment. This
had, however, to be done manually and represented a
fairly heavy workload. The extra 20 records selected from
the database to compensate for exclusions did not always
make up for the recorded 28 % exclusion rate.
A second hurdle was that, in the French health care
system, each hospital does not have access to all the data
on a given patient. For example, QI 4 and QI 5 could
not be calculated when follow-up or all care did not take
place within the same hospital (e.g. appointment in pri-
vate practice (QI 4), and appointment in one hospital
with treatment in another hospital (QI 5)). The situation
was even more complex when these hospitals had a dif-
ferent status (public, private, or not-for-profit).
A third hurdle, which also represent a limitation of
our results, was that criteria on waiting times and
delays are based on consensus among experts and not
on standards derived from practice guidelines with a
high level of evidence, which are normally used to
construct QIs. Each country has its own standards
[33]. The good practice guide produced in 2009 by
the National Collaborating Centre for Cancer for
NICE (National Institute for Health and Clinical Ex-
cellence) recommends not more than a 4-week delay
from diagnosis to treatment, and starting chemother-
apy or radiotherapy within 31 days of surgery [34]. In
contrast, French guidelines published back in 2002
recommend a 21-day delay from the first appointment
with the surgeon to surgery (similarly to the National
Initiative on Cancer Care Quality (NICCQ) recom-
mendation in the US [33]), a 30-day delay from sur-
gery to chemotherapy, and 56 days from surgery to
radiotherapy [25].
This hurdle could be partly overcome by using as tar-
gets the proportion of patients treated within set times.
Such targets better satisfy health professionals for whom
delays should reflect organisational constraints and not
include patient-related causes (e.g. patient not turning
up for the appointment, treatment postponed at thepatient’s request). According to European guidelines, a
threshold of 90 % is acceptable for ≤15 working days be-
tween the decision to operate and surgery and 70 % for
≤10 days [3]. According to EUSOMA, the minimum
standard is >75 % and the target is >90 % for surgery
performed within 6 weeks after the first diagnostic
examination in the breast unit [4]. The Dutch auditing
system has established a 90 % standard for 5 QIs [35].
However, a comparison with our results is difficult be-
cause of differences in QI definitions. Should the French
health authorities take 90 % of patients registered in
each time period as standard, there is much room for
improvement in many hospitals as shown in Table 2.
Recent experiences in Europe and the USA have
shown that QI implementation at a local [33]. or na-
tional level using a variety of methodologies can improve
the quality of care of breast cancer patients but that this
takes time [35-37]. According to the Dutch experience,
none of 9 QIs met standards in 2002 whereas 4 did in
2008, with a significant improvement in all 9 QIs. Be-
cause hospitals simply perform better when they know
they are being evaluated (Hawthorne effect), but also be-
cause comparison is able to promote a better registra-
tion process and compliance with best clinical practice,
improvements can be expected in France also.
Whether QI scores may qualify hospitals in the certifi-
cation of breast cancer centres is a moot point. We
could propose to follow the example of the National
Quality Measures for Breast Care (NQMBC), which uses
the degree of participation to on-line registration of the
answers to a set of quality questions to grant 3 levels of
certification for quality breast health care [17,36].Conclusions
Our selected QIs on timeliness of breast cancer care
proved feasible and applicable in the clinic. Their imple-
mentation was highly dependent on care organisation,
patient behaviour, and the quality of the information sys-
tems used by French hospitals. Future QIs should cover
the entire care pathway from before to after hospital
consultations and admission, and should include the
patient’s perspective [7,38]. The COMPAQ-HPST pro-
ject is currently focusing on the construction of QIs cov-
ering care from an abnormal screening result right
through to post-treatment follow-up, as in the ambitious
programme developed by the American Society of Clin-
ical Oncology (ASCO) [39]. This is a challenge because
of the need to merge patient databases that are managed
by hospitals using information systems that are often
not compatible and of the need to guarantee access to
these data. The challenge is even greater at the European
level where account has to be taken of differences in the
organisation of care among countries.
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